EYEVENSYS

Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. EyeCET stands for the eye ciliary muscle electro-transfection technology, which uses electroporation to deliver plasmids coding for therapeutic proteins in the eye. EyeCET is safe and non-viral, and it enables the ciliary muscle cells to sustainably produce therapeutic proteins locally. Eyevensys believes its EyeCET technology can improve short and long-term therapeutic outcomes, greatly enhancing patient compliance and significantly improve the tolerability of treatment. Eyevensys lead product EYS606 is a potential new treatment for patients with non-infectious Uveitis (NIU), the 4th cause of blindness in the world. EYS606 uses Eyevensys proprietary electro-transfection injection system (ETIS) to deliver a plasmid encoding for the production of an anti-TNF a...